

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_86004
Title of the Manuscript:	Molecular Docking Analysis of Bacoside A with selected Signalling factors Involved in Glioblastoma
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalipri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	This manuscript reports on a systematic analysis by molecular docking of the potential interactions between Bacoside A and several molecules involved in pathways known to be disturbed in cancer. Although this rationale is interesting, the authors base it on rather ancient literature while more recent studies could strengthen their choices. The in vitro study of Bacoside toxicity on a glioblastoma cell line does not add much to this work. In addition to the work by Aisha et al. mentioned by the authors, the more recent report by Moskwa et al. in 2020 would be sufficient to support the in silico study. A suggestion from this reviewer would be to remove the paragraph on Ayurvedic from the introduction and rather place here the part now appearing as "protein selection" for molecular docking, slightly shortened and with a bibliographic update. Then the bioinformatics study would be more logically introduced. The discussion could expand the results focused on glioblastoma by elaborating on the possible consequences of Bacoside binding to cell viability and extend this to other cancers.	
Minor REVISION comments	The whole manuscript requires thorough editing for grammar and typos. Drugs should be named by their international nonproprietary names in lower case.	
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

Reviewer Details:

Name:	Bene Mc
Department, University & Country	Nantes University, France